Our results demonstrate that STAT6 inhibition enhances iTreg differentiation and mitigates inflammation, though this immunomodulation alone is insufficient to prevent CAC development, highlighting the complexity of tumor-immune interactions in chronic inflammation. Here, STAT6 is linked to neoplasm.